2023-505933-29-00RecruitingPhase 2
Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associated Glycoprotein antibodies related polyneuropathy and Zanubrutinib Treatment
University Medical Center Utrecht2 sites in 1 country42 target enrollmentStarted: October 27, 2023Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 42
- Locations
- 2
- Primary Endpoint
- Proportion of patients with ≥2 points improvement on the Inflammatory Neuropathy Cause and Treatment disability score (INCATds) at the end of cycle 12 (1 year from baseline)
Study Overview
Brief Summary
We want to investigate the use of Zanubrutinib in combination with standard therapy Rituximab for the possible improvement on the neurological outcome in patients with immunoglobulin M (IgM) monoclonal gammopathy of unknown significance (MGUS) anti-MAG polyneuropathy after 12 months, based on the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. In addition, we want to investigate safety, tolerability and drug adherence of this treatment.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Able to provide written informed consent and understand and comply with the requirements of the study
- •No history of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
- •Previous treatment with intravenous immunoglobulins is allowed if > 3 months before inclusion
- •Previous treatment for polyneuropathy with Anti CD20 monoclonal antibody (MoAb) and/or cyclophosphamide is allowed only if given > 6 months before inclusion. Patients without previous response to Rituximab >6 months before inclusion can be included.
- •Demyelinating polyneuropathy defined by the European Federation of Neurological Societies (EFNS) / Peripheral Nerve Society (PNS) guideline on management of paraproteinemic demyelinating neuropathies
- •Functional impairment; defined as an Inflammatory Neuropathy Cause and Treatment disability score (INCATds) of ≥2
- •Age ≥ 18 years
- •IgM monoclonal gammopathy of unknown significance (MGUS), defined as the presence of an IgM M-protein (detectable but < 30 g/L) AND elevated total IgM level in serum
- •Presence of anti MAG antibodies ≥ 10.000 titer units, measured with the Bühlmann ELISA
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2
- •Adequate hematological laboratory values defined as hemoglobin ≥ 6.0 mmol/L, neutrophils > 1.0 × 10^9/L and platelets > 100 × 10^9/L
- •Adequate hepatic and renal function laboratory values defined as ASAT/ALAT < 3 × upper limit of normal (ULN), bilirubin < 1.5× ULN and creatinine clearance ≥ 30 ml/min
Exclusion Criteria
- •Hematological malignancy e.g., known Multiple Myeloma or confirmed Waldenström’s Macroglobulinemia based on bone marrow analysis
- •Prior treatment with purine analogues (fludarabine or cladribine)
- •Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor
- •Major surgery within 4 weeks of study treatment
- •Participation in another interventional clinical trial
- •Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- •Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy that was completed ≤ 14 days before the first dose of study drug
- •Active tuberculosis
- •Infection with human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B or hepatitis C infection. Patients with presence of hepatitis C virus (HCV) antibody are eligible if HCV ribonucleic acid (RNA) is undetectable. Patients with a serologic status reflecting prior or active hepatitis B cannot be included. We will test the hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibodies (anti-HBc) and anti-hepatitis B surface antibodies (anti-HBs) at screening. Patients with a serological status reflecting an earlier hepatitis B vaccination (HBsAg negative / antiHBc negative / anti-HBs positive) may be included. Other combinations are not allowed.
- •At time of study entry, taking any medications which are strong CYP3A inhibitors (e.g., conivaptan, posaconazole, voriconazole, ketoconazole, itraconazole, clarithromycin, indinavir, lopinavir, ritonavir, telaprevir) or strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, St. John’s wort)
- •Intolerance to previous Rituximab treatment
- •Pregnant women, women with child-bearing potential (WOCBP) not able or willing to prevent pregnancy and lactating women as well. WOCBP will agree to use highly effective contraception for the duration of the trial treatment and for 12 months after Rituximab treatment stop or 120 days after Zanubrutinib treatment stop, whichever has a longer duration. Participants using hormonal contraceptives (e.g., birth control pills or devices) must use a barrier method of contraception (e.g., condoms) as well.
- •History of intolerance to the active ingredients or other ingredients of Zanubrutinib
- •Other known concomitant causes of chronic (demyelinating) polyneuropathy, including Charcot Marie Tooth Disease, other hereditary neuropathies, diabetes mellitus, use of amiodarone, past or current dependence on alcohol, other lymphoma or malignant blood dyscrasias, previous Guillain-Barré syndrome
- •Currently active, clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease (congestive heart failure) as defined by the New York Heart Association (NYHA) Functional Classification, or history of myocardial infarction within 6 months of screening
- •A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening: QTcF >450 msec (males); QTcF >460 msec (females); History of familial long QT syndrome or known family history of Torsade de Pointes; Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study; Second degree atrioventricular (AV) block Type II, or third-degree AV block. Controlled atrial fibrillation is allowed.
- •Any history of malignancy of any organ system (other than localized basal or squamous cell carcinoma of the skin, superficial bladder cancer or carcinoma in situ of the cervix or breast), treated or untreated within the last 3 years
- •History of ischemic stroke within 180 days before first dose of Zanubrutinib
- •History of central nervous system (CNS) hemorrhage
- •History of inherited or acquired hemorrhagic disorder
Outcomes
Primary Outcomes
Proportion of patients with ≥2 points improvement on the Inflammatory Neuropathy Cause and Treatment disability score (INCATds) at the end of cycle 12 (1 year from baseline)
Proportion of patients with ≥2 points improvement on the Inflammatory Neuropathy Cause and Treatment disability score (INCATds) at the end of cycle 12 (1 year from baseline)
Incidence of adverse events during treatment and follow up (36 months from baseline), graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Incidence of adverse events during treatment and follow up (36 months from baseline), graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Dose adjustments made per patient
Dose adjustments made per patient
Registration of drug accountability (counting of remaining capsules after each treatment cycle). Drug accountability will be presented as percentage.
Registration of drug accountability (counting of remaining capsules after each treatment cycle). Drug accountability will be presented as percentage.
Secondary Outcomes
- Hematological response rate (including progression) at 6, 12, 24 and 36 months
- Best achieved hematological response rate during treatment and follow-up
- Change from baseline on the Inflammatory Neuropathy Cause and Treatment disability score (INCATds) after 3, 6, 10, 12, 18, 24 and 36 months, at the end of treatment and the end of study
- Change from baseline on the Rasch-built Overall Disability Scale for immune-mediated peripheral neuropathies (iRODS) after 3, 6, 10, 12, 18, 24 and 36 months, at the end of treatment and the end of study
- Change from baseline on the Overall Neuropathy Limitations Scale (ONLS) after 3, 6, 10, 12, 18, 24 and 36 months, at the end of treatment and the end of study
- Change from baseline on the 10 meter walk test after 3, 6, 10, 12, 18, 24 and 36 months, at the end of treatment and the end of study
- Change from baseline on the ataxia score after 3, 6, 10, 12, 18, 24 and 36 months, at the end of treatment and the end of study
- Change from baseline on the modified Inflammatory Neuropathy Cause And Treatment (INCAT) sensory sum score after 3, 6, 10, 12, 18, 24 and 36 months, at the end of treatment and the end of study
- Change from baseline on the grip strength (vigorimetry) after 3, 6, 10, 12, 18, 24 and 36 months, at the end of treatment and the end of study
- Registration of hematological progression (and other responses) during treatment and follow-up to assess hematological progression free survival and time to progression
- Death registration during treatment and follow up. Overall survival is defined as time from inclusion to death (or end of follow-up)
- Change from baseline in Bühlmann ELISA titer units, measured after every 2 cycles during treatment and every 6 months during follow-up
- Evaluation of molecular markers at diagnosis. Performed using next generation sequencing (NGS) for CXCR4 mutations and the MYD88L265P mutation after CD19 selection of bone marrow aspirate at central laboratory.
- At baseline, a complete panel of anti-neural antibodies will be performed (only if not done previously), that consists of gangliosides GM1, GM2, GD1a and GD1b.
- Relation of neurological and hematological response endpoints with molecular markers at diagnosis.
- Relation of molecular markers with anti-MAG titer
- Time to first hematological and first neurological response
- Time to maximum hematological and maximum neurological response
- Duration of hematological and neurological response during follow up period
- Relation of immunological parameters with neurological endpoints
- Change from baseline on the quality of life assessment (EQ-5D-5L) measured after 6, 12, 18, 24, 30 and 36 months, at the end of treatment and the end of study
- Change from baseline on the patients global impression of change (PGIC) assessment, measured after 6, 12, 18, 24, 30 and 36 months, at the end of treatment and the end of study
Investigators
Clinical trial management hematology
Scientific
University Medical Center Utrecht
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 4
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaHemophagocytic LymphohistiocytosisNCT07270835The First Affiliated Hospital of Soochow University40
Not yet recruiting
Phase 2
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaNCT07259122Institute of Hematology & Blood Diseases Hospital, China43
Recruiting
Phase 2
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaMantle Cell LymphomaNCT07261163Institute of Hematology & Blood Diseases Hospital, China37
Recruiting
Phase 3
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in comparison to placebo with omalizumab as active control in adult patients with CSU and inadequate response to H1-antihistamine and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.2022-502161-19-00Novartis Pharma AG214
Recruiting
Phase 2
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52